What is Optimed Research?
Founded by Dr. Donald McNeil, Optimed Research operates as a sophisticated clinical research organization (CRO) with a focus on Allergy, Immunology, Ophthalmology, and Neurology. The company distinguishes itself through the integration of cloud-based technology and real-time data capture, which streamlines the drug development lifecycle. By bridging the gap between patients, physicians, and pharmaceutical sponsors, Optimed Research facilitates efficient trial management, ensuring that innovative therapies reach the market with greater speed and precision. Their established presence in the clinical research sector makes them a critical partner for entities seeking to navigate the complexities of modern medical development.
How much funding has Optimed Research raised?
Optimed Research has raised a total of $304K across 2 funding rounds:
Debt
$150K
Debt
$154K
Debt (2020): $150K with participation from PPP
Debt (2021): $154K led by PPP
Key Investors in Optimed Research
PPP
Public-Private Partnership
What's next for Optimed Research?
With this late-stage capital injection, Optimed Research is expected to prioritize the expansion of its digital trial management platforms and the broadening of its clinical site footprint. The strategic focus will likely shift toward enhancing data interoperability and patient recruitment efficiency, which are essential for maintaining a competitive edge in the high-stakes pharmaceutical research market. As the firm continues to scale, the integration of advanced analytics will be pivotal in maintaining its reputation for quality and reliability in Phase IV post-market surveillance studies. This growth trajectory suggests a long-term commitment to optimizing the clinical trial ecosystem through technological innovation and operational excellence.
See full Optimed Research company page
